Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Clinical Sciences, Lund University, Malmö, Sweden; Department of Population Medicine, Qatar University College of Medicine, QU Health, Doha, Qatar.
Programs in Metabolism and Medical & Population Genetics, Broad Institute, Cambridge, MA 02142, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
Am J Hum Genet. 2022 Jan 6;109(1):81-96. doi: 10.1016/j.ajhg.2021.11.021. Epub 2021 Dec 20.
Large-scale gene sequencing studies for complex traits have the potential to identify causal genes with therapeutic implications. We performed gene-based association testing of blood lipid levels with rare (minor allele frequency < 1%) predicted damaging coding variation by using sequence data from >170,000 individuals from multiple ancestries: 97,493 European, 30,025 South Asian, 16,507 African, 16,440 Hispanic/Latino, 10,420 East Asian, and 1,182 Samoan. We identified 35 genes associated with circulating lipid levels; some of these genes have not been previously associated with lipid levels when using rare coding variation from population-based samples. We prioritize 32 genes in array-based genome-wide association study (GWAS) loci based on aggregations of rare coding variants; three (EVI5, SH2B3, and PLIN1) had no prior association of rare coding variants with lipid levels. Most of our associated genes showed evidence of association among multiple ancestries. Finally, we observed an enrichment of gene-based associations for low-density lipoprotein cholesterol drug target genes and for genes closest to GWAS index single-nucleotide polymorphisms (SNPs). Our results demonstrate that gene-based associations can be beneficial for drug target development and provide evidence that the gene closest to the array-based GWAS index SNP is often the functional gene for blood lipid levels.
大规模的复杂性状基因测序研究有可能识别出具有治疗意义的因果基因。我们对来自多个种族的超过 17 万名个体的序列数据进行了基于基因的血脂水平关联测试,这些个体的稀有(次要等位基因频率<1%)预测有害编码变异。研究对象包括 97493 名欧洲人、30025 名南亚人、16507 名非洲人、16440 名西班牙裔/拉丁裔人、10420 名东亚人和 1182 名萨摩亚人。我们鉴定出了 35 个与循环血脂水平相关的基因;其中一些基因在使用基于人群样本的稀有编码变异时,以前与血脂水平没有关联。我们根据稀有编码变异的聚集,对基于阵列的全基因组关联研究(GWAS)基因座中的 32 个基因进行了优先级排序;其中三个(EVI5、SH2B3 和 PLIN1)以前与血脂水平的稀有编码变异没有关联。我们大多数相关基因在多个种族中都显示出关联的证据。最后,我们观察到基于基因的关联在低密度脂蛋白胆固醇药物靶点基因和与 GWAS 索引单核苷酸多态性(SNP)最接近的基因中存在富集。我们的研究结果表明,基于基因的关联对药物靶点的开发有益,并提供了证据表明,与基于阵列的 GWAS 索引 SNP 最接近的基因通常是血液脂质水平的功能基因。